The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
p63 is a cereblon substrate involved in thalidomide teratogenicity
Abstract
Cereblon (CRBN) is a primary target of thalidomide and mediates its multiple pharmacological activities, including teratogenic and antimyeloma activities. CRBN functions as a substrate receptor of the E3 ubiquitin ligase CRL4, whose substrate specificity is modulated by thalidomide and its analogs. Although a number of CRL4 CRBN substrates have recently been identified, the substrate involved in thalidomide teratogenicity is unclear. Here we show that p63 isoforms are thalidomide-dependent CRL4 CRBN neosubstrates that are responsible, at least in part, for its teratogenic effects. The p53 family member p63 is associated with multiple developmental processes. ∆Np63α is essential for limb development, while TAp63α is important for cochlea development and hearing. Using a zebrafish model, we demonstrate that thalidomide exerts its teratogenic effects on pectoral fins and otic vesicles by inducing the degradation of ∆Np63α and TAp63α, respectively. These results may contribute to the invention of new thalidomide analogs lacking teratogenic activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“thalidomide-induced degradation of SAll4, and to some extent PlZF and p63 (Asatsuma-Okumura et al. 2019;yamanaka et al. 2021), was confirmed as the root cause of the teratogenic deformities affecting thousands of babies (Matyskiela et al. 2018).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Asatsuma-Okumura et al. 2019
In the citing paper
“The subcellular localizations of these factors differ: the transcription factors Ikaros, Aiolos, and MEIS2 are localized to the nucleus, whereas GSPT1, CK1α, and glutamine synthetase reside in the cytoplasm.”
From Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide (2020) · cites this paper as [15]
In the citing paper
“To date, over a dozen proteins including Ikaros, Aiolos, GSPT1, CK1α, glutamine synthetase, MEIS2, KCNMA1/SLO1, CLC1, and AMPKα have been identified as substrates for CRBN3,11–16,24–28.”
From Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide (2020) · cites this paper as [15]
In the citing paper
“The subcellular localizations of these factors differ: the transcription factors Ikaros, Aiolos, and MEIS2 are localized to the nucleus, whereas GSPT1, CK1α, and glutamine synthetase reside in the cytoplasm.”
From Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide (2020) · cites this paper as [15]
Citations
Cites
High-resolution in situ hybridization to whole-mount zebrafish embryos
Thisse, C., & Thisse, B. (2007) · Nature Protocols · doi:10.1038/nprot.2007.514 · Cited by 2,587
Effective targeted gene ‘knockdown’ in zebrafish
Nasevicius, A., & Ekker, S. C. (2000) · Nature Genetics · doi:10.1038/79951 · Cited by 2,485
p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development
Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C. J., Sharpe, A. H., Caput, D., Crum, C. P., et al. (1999) · Nature · doi:10.1038/19539 · Cited by 2,264
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Self-citationp63 is a p53 homologue required for limb and epidermal morphogenesis
Mills, A. A., Zheng, B., Wang, X., Vogel, H. S., Roop, D. R., & Bradley, A. (1999) · Nature · doi:10.1038/19531 · Cited by 2,015
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Thalidomide-induced Teratogenesis: History and Mechanisms
Vargesson, N. (2015) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.21096 · Cited by 912
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K. S., & Dalgleish, A. G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1323 · Cited by 817
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature · doi:10.1038/nature18611 · Cited by 701
Self-citationStructural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620
Donovan, K. A., An, J., Nowak, R. P., Yuan, J. C., Fink, E. C., Berry, B. C., Ebert, B. L., & Fischer, E. S. (2018) · eLife · doi:10.7554/elife.38430 · Cited by 509
Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
Parman, T., Wiley, M. J., & Wells, P. G. (1999) · Nature Medicine · doi:10.1038/8466 · Cited by 495
Fgf8 signalling from the AER is essential for normal limb development
Lewandoski, M., Sun, X., & Martin, G. R. (2000) · Nature Genetics · doi:10.1038/82609 · Cited by 451
Fgf8 is required for outgrowth and patterning of the limbs
Moon, A., & Capecchi, M. (2000) · Nature Genetics · doi:10.1038/82601 · Cited by 347
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
Matyskiela, M. E., Couto, S., Zheng, X., Lu, G., Hui, J., Stamp, K., Drew, C., Ren, Y., Wang, M., Carpenter, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0129-x · Cited by 338
Structure of a DNA-bound Ultrabithorax–Extradenticle homeodomain complex
Passner, J. M., Ryoo, H. D., Shen, L., Mann, R. S., & Aggarwal, A. K. (1999) · Nature · doi:10.1038/17833 · Cited by 312
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
Matyskiela, M. E., Zhang, W., Man, H.-W., Muller, G., Khambatta, G., Baculi, F., Hickman, M., LeBrun, L., Pagarigan, B., Carmel, G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01921 · Cited by 309
Bakkers, J., Hild, M., Kramer, C., Furutani‐Seiki, M., & Hammerschmidt, M. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00163-6 · Cited by 213
The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development
Rehman, W., Arfons, L. M., & Lazarus, H. M. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711413165 · Cited by 207
Hagner, P. R., Man, H.-W., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C. G., Lu, G., Rychak, E., et al. (2015) · Blood · doi:10.1182/blood-2015-02-628669 · Cited by 203
Eichner, R., Heider, M., Fernández-Sáiz, V., van Bebber, F., Garz, A.-K., Lemeer, S., Rudelius, M., Targosz, B.-S., Jacobs, L., Knorn, A.-M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4128 · Cited by 183
pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
An, J., Ponthier, C. M., Sack, R., Seebacher, J., Stadler, M. B., Donovan, K. A., & Fischer, E. S. (2017) · Nature Communications · doi:10.1038/ncomms15398 · Cited by 176
Pattern of p63 mutations and their phenotypes—update
Rinne, T., Hamel, B. C. J., van Bokhoven, H., & Brunner, H. G. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31271 · Cited by 165
Yu, K., & Ornitz, D. M. (2007) · Development · doi:10.1242/dev.013268 · Cited by 136
Hans, S., Liu, D., & Westerfield, M. (2004) · Development · doi:10.1242/dev.01346 · Cited by 128
Laterality patterns in infants with external birth defects
Paulozzi, L. J., & Lary, J. M. (1999) · Teratology · doi:10.1002/(sici)1096-9926(199911)60:5 · Cited by 118
Ramsey, M. R., He, L., Forster, N., Ory, B., & Ellisen, L. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0046 · Cited by 106
Wang, G. X., Tu, H.-C., Dong, Y., Skanderup, A. J., Wang, Y., Takeda, S., Ganesan, Y. T., Han, S. I., Liu, H., Hsieh, J. J.-D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.030 · Cited by 78
Lee, K. M., Yang, S.-J., Kim, Y. D., Choi, Y. D., Nam, J. H., Choi, C. S., Choi, H.-S., & Park, C.-S. (2013) · Diabetes · doi:10.2337/db12-1030 · Cited by 77
Hansen, J. M., Harris, K. K., Philbert, M. A., & Harris, C. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.768 · Cited by 66
Latina, A., Viticchiè, G., Lena, A. M., Piro, M. C., Annicchiarico‐Petruzzelli, M., Melino, G., & Candi, E. (2015) · Oncogene · doi:10.1038/onc.2015.222 · Cited by 63
Chung, F., Lu, J., Palmer, B. D., Kestell, P., Browett, P., Baguley, B. C., Tingle, M. D., & Ching, L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0421 · Cited by 62
TAp63 Is Important for Cardiac Differentiation of Embryonic Stem Cells and Heart Development
Rouleau, M., Medawar, A., Hamon, L., Shivtiel, S., Wolchinsky, Z., Zhou, H., Rosa, L. D., Candi, E., Divonne, S. B.-D. L. F., Mikkola, M. L., et al. (2011) · Stem Cells · doi:10.1002/stem.723 · Cited by 59
Nitric oxide rescues thalidomide mediated teratogenicity
Siamwala, J. H., Veeriah, V., Priya, M. K., Rajendran, S., Saran, U., Sinha, S., Nagarajan, S., Pratheep, T., & Chatterjee, S. (2012) · Scientific Reports · doi:10.1038/srep00679 · Cited by 54
Beedie, S., Rore, H. M., Barnett, S., Chau, C. H., Luo, W., Greig, N. H., Figg, W. D., & Vargesson, N. (2016) · Oncotarget · doi:10.18632/oncotarget.8909 · Cited by 45
Restelli, M., Lopardo, T., Iacono, N. L., Garaffo, G., Conte, D., Rustighi, A., Napoli, M., Sal, G. D., Pérez-Morga, D. L., Costanzo, A., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu096 · Cited by 44
Self-citationRole of p63 and the Notch pathway in cochlea development and sensorineural deafness
Terrinoni, A., Serra, V., Bruno, E., Strasser, A., Valente, L. J., Flores, E. R., van Bokhoven, H., Lü, X., Knight, R. A., & Melino, G. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214498110 · Cited by 43
S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation
Lapi, E., Iovino, A. J., Fontemaggi, G., Soliera, A. R., Iacovelli, S., Sacchi, A., Rechavi, G., Givol, D., Blandino, G., & Strano, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209401 · Cited by 42
Ichikawa, T., Suenaga, Y., Koda, T., Ozaki, T., & Nakagawara, A. (2007) · Oncogene · doi:10.1038/sj.onc.1210658 · Cited by 38
Structural basis of p63α SAM domain mutants involved in AEC syndrome
Sathyamurthy, A., Freund, S. M. V., Johnson, C. M., Allen, M. D., & Bycroft, M. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08194.x · Cited by 23
P63 expression plays a role in developmental rate, embryo size, and local morphogenesis
Boughner, J. C., van Eede, M. C., Spring, S., Yu, L. X., Rostampour, N., & Henkelman, R. M. (2018) · Developmental Dynamics · doi:10.1002/dvdy.24622 · Cited by 19
Jiang, L., Li, K., Lin, Q., Ren, J. M., He, Z., Li, H., Shen, N., Wei, P., Feng, F., & He, M. (2016) · Reproductive Toxicology · doi:10.1016/j.reprotox.2016.06.004 · Cited by 16
Zhao, X., Jiang, B., Hu, H., Mao, F., Mi, J., Li, Z., Liu, Q., Shao, C., & Gong, Y. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu503 · Cited by 15
Efficient Transfection Strategy for the Spatiotemporal Control of Gene Expression in Zebrafish
Ando, H., & Okamoto, H. (2006) · Marine Biotechnology · doi:10.1007/s10126-005-5138-6 · Cited by 8
Self-citationSaxena, A., & Cooper, K. L. (2016) · Nature · doi:10.1038/nature19425 · Cited by 7
Cited by
Sorted by citations
Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K., Kanıskan, H. Ü., Xiong, Y., & Jin, J. J. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00365-x · Cited by 680
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Nalawansha, D. A., & Crews, C. M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 520
Proteolysis‐targeting chimeras in drug development: A safety perspective
Moreau, K., Coen, M., Zhang, A. X., Pachl, F., Castaldi, M. P., Dahl, G., Boyd, H., Scott, C., & Newham, P. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15014 · Cited by 229
Targeted protein degradation for cancer therapy
Hinterndorfer, M., Spiteri, V. A., Ciulli, A., & Winter, G. E. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00817-8 · Cited by 245
Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective
Luh, L. M., Scheib, U., Juenemann, K., Wortmann, L., Brands, M., & Cromm, P. M. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004310 · Cited by 203
Metadata
- Authors
- Asatsuma-Okumura, T., Ando, H., De Simone, M., Yamamoto, J., Sato, T., Shimizu, N., Asakawa, K., Yamaguchi, Y., Ito, T., Guerrini, L., & Handa, H.
- Affiliations
- Tokyo Medical University (JP)
- Tokyo Institute of Technology (JP)
- University of Milan (IT)
- Corresponding author
- Guerrini, Luisa
- Handa, Hiroshi
- ORCID
- Venue
- Nature Chemical Biology
- Published
- 2019-10-07
- Volume
- 15
- Issue
- 11
- Pages
- 1077-1084
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2978105110
- Cited by
- 134
- References
- 50
- Citations by year
- 2026: 6 · 2025: 23 · 2024: 14 · 2023: 19 · 2022: 23 · 2021: 24 · 2020: 25
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- MEXT | Japan Society for the Promotion of Science (15H04288, 17K14996, 17H06112, S1411011)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Keywords
- thalidomide, cereblon, p63, teratogenicity, p53 family, ΔNp63α, TAp63α, limb development, cochlear development, zebrafish, thalidomide analogues
- MeSH terms
- Humans, Membrane Proteins, Substrate Specificity, Teratogens, Thalidomide, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
